ONCODES.PREC.MED. EO-34 Working Capital to Net Assets Ratio
ONCODES.PREC.MED. EO-34 working capital to net assets ratio. ONCODES.PREC.MED. EO-34 (ZR8) has a Working Capital to Net Assets ratio of -1178.1% as of December 2024. Working capital of €5.06 Million (current assets of €8.67 Million minus current liabilities of €3.61 Million) is measured against net assets of €-429.39K. A higher ratio indicates strong short-term liquidity financed by the equity base. Check ZR8 goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Working Capital to Net Assets Ratio of ONCODES.PREC.MED. EO-34 (2021–2024)
Working capital to net assets ratio of ONCODES.PREC.MED. EO-34 from 2021 to 2024. This chart shows how ONCODES.PREC.MED. EO-34's Working Capital to Net Assets ratio has evolved across 4 annual periods from 2021 to 2024. As of December 2024, the ratio stands at -1178.1%, reflecting working capital of €5.06 Million against net assets of €-429.39K EUR. See ZR8 cash and liquid assets coverage to measure how many days the company can operate on defensive assets alone.
ONCODES.PREC.MED. EO-34 Working Capital to Net Assets Ratio by Year (2021–2024)
ONCODES.PREC.MED. EO-34 working capital to net assets ratio by year from 2021 to 2024. The table below presents the year-by-year Working Capital to Net Assets ratio for ONCODES.PREC.MED. EO-34 from 2021 to 2024, covering 4 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For the complete balance sheet picture, see ZR8 total assets.
| Year | WC/NA Ratio | Working Capital (EUR) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2024 | -1178.1% | €5.06 Million | €-429.39K | €8.67 Million | €3.61 Million | ▼ -1456.9 pp |
| 2023 | 278.8% | €10.29 Million | €3.69 Million | €14.40 Million | €4.11 Million | ▲ +173.2 pp |
| 2022 | 105.6% | €12.45 Million | €11.78 Million | €16.41 Million | €3.96 Million | ▼ -21.0 pp |
| 2021 | 126.6% | €5.32 Million | €4.20 Million | €6.53 Million | €1.21 Million | — |